Translational nanoparticle engineering for cancer vaccines

OncoImmunology

卷:6

Elias J. Sayour¹  Adam J. Grippin¹  Duane A. Mitchell¹ 

[1] Preston A. Wells, Jr. Center for Brain Tumor Therapy, University of Florida Brain Tumor Immunotherapy Program, McKnight Brain Institute;

关键词: cancer immunotherapy;    clinical trials;    cancer vaccines;    liposomes;    nanoparticles;   

DOI  :  10.1080/2162402X.2017.1290036

来源: DOAJ

【 摘 要 】

Conventional cancer treatments remain insufficient to treat many therapy-resistant tumors. Cancer vaccines attempt to overcome this resistance by activating the patient's immune system to eliminate tumor cells without the toxicity of systemic chemotherapy and radiation. Nanoparticles (NPs) are promising as customizable, immunostimulatory carriers to protect and deliver antigen. Although many NP vaccines have been investigated in preclinical settings, a few have advanced into clinical application, and still fewer have demonstrated clinical benefit. This review incorporates observations from NP vaccines that have been evaluated in early phase clinical trials to make recommendations for the next generation of NP-based cancer vaccines.

【 授权许可】

Unknown